Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Nephrology
Published in: Clinical and Experimental Nephrology 4/2012

01-08-2012 | Original Article

A lower level of reduced albumin induces serious cardiovascular incidence among peritoneal dialysis patients

Authors: Hiroyuki Terawaki, Yukie Matsuyama, Nanae Matsuo, Makoto Ogura, Jun Mitome, Akihiko Hamaguchi, Tomoyoshi Terada, Seiichi Era, Tatsuo Hosoya

Published in: Clinical and Experimental Nephrology | Issue 4/2012

Login to get access

Abstract

Background

Human serum albumin is composed of human mercaptoalbumin (HMA) with cysteine residues having reducing powers and of oxidized human non-mercaptoalbumin. Previously, we reported that a lower HMA level is closely related to serious cardiovascular disease (CVD) incidence and mortality among hemodialysis patients. However, the relationship between HMA level and CVD incidence among peritoneal dialysis (PD) patients is unclear.

Methods

We measured the redox state of human serum albumin using high-performance liquid chromatography in 30 continuous ambulatory PD patients. The association between HMA and incidental CVD events was evaluated.

Results

Eight patients experienced symptomatic CVD events (5 patients died) at the 5-year follow-up. The concentration and fraction of HMA (cHMA and f(HMA), respectively) showed significantly lower values in patients with CVD than those without CVD (cHMA 1.58 ± 0.39 and 2.16 ± 0.43 g/dL, f(HMA) 48.9 ± 5.4 and 56.4 ± 8.6%, respectively). Multiple forward stepwise regression analysis using cHMA and f(HMA) as the criterion variables was performed, and C-reactive protein and hemoglobin were adopted as significant explanatory variables in the former equation, whereas urea nitrogen was adopted in the latter equation. Multiple logistic regression analysis revealed that cHMA is a statistically, and f(HMA) is a marginally significant explanatory variable of CVD incidence (p = 0.0369, R = −0.260 and p = 0.0580, R = −0.214, respectively).

Conclusions

Lower HMA level, which might be caused by chronic inflammation, anemia and accumulation of dialyzable uremic toxin(s), is closely related to serious CVD incidence among PD patients.
Literature
1.
Nakai S, Suzuki K, Masakane I, Wada A, Itami N, Ogata S, et al. Overview of regular dialysis treatment in Japan (as of 31 December 2008). Ther Apher Dial. 2010;14:505–40.PubMedCrossRef
2.
Terawaki H, Takada Y, Era S, Funakoshi Y, Nakayama K, Nakayama M, et al. The redox state of albumin and serious cardiovascular incidence in hemodialysis patients. Ther Apher Dial. 2010;14:465–71.PubMedCrossRef
3.
Ogasawara Y, Namai T, Togawa T, Ishii K. Formation of albumin dimers induced by exposure to peroxides in human plasma: a possible biomarker for oxidative stress. Biochem Biophys Res Commun. 2005;340:353–8.PubMedCrossRef
4.
Terawaki H, Nakayama K, Matsuyama Y, Nakayama M, Sato T, Hosoya T, et al. Dialyzable uremic solutes contribute to enhanced oxidation of serum albumin in regular hemodialysis patients. Blood Purif. 2007;25:274–9.PubMedCrossRef
5.
Sogami M, Nagoka S, Era S, Honda M, Noguchi K. Resolution of mercapt- and nonmercaptalbumin by high-performance liquid chromatography. Int J Peptide Protein Res. 1984;24:96–103.CrossRef
6.
Sogami M, Era S, Nagaoka S, Kuwata K, Kida K, Miura K, et al. HPLC-studies on nonmercapt–mercapt conversion of human serum albumin. Int J Peptide Protein Res. 1985;25:398–402.CrossRef
7.
Era S, Hamaguchi T, Sogami M, Kuwata K, Suzuki E, Miura K, et al. Further studies on the resolution of human mercapt- and non-mercaptalbumin and on human serum albumin in the elderly by high-performance liquid chromatography. Int J Peptide Protein Res. 1988;31:435–42.CrossRef
8.
Era S, Kuwata K, Imai I, Nakamura K, Hayashi T, Sogami M. Age-related change in redox state of human serum albumin. Biochim Biophys Acta. 1995;1247:12–6.PubMedCrossRef
9.
Imai H, Hayashi T, Negawa T, Nakamura K, Tomida M, Koda K, et al. Strenuous exercise-induced change in redox state of human serum albumin during intensive kendo training. Jpn J Physiol. 2002;52:135–40.PubMedCrossRef
10.
Sogami M, Era S, Nagaoka S, Kuwata K, Kida K, Shigemi J, et al. High-performance liquid chromatographic studies on non-mercapt in equilibrium with mercapt conversion of human serum albumin. II. J Chromatogr. 1985;332:19–27.PubMedCrossRef
11.
Fukushima H, Miwa Y, Shiraki M, Gomi I, Toda K, Kuriyama S, et al. Oral branched-chain amino acid supplementation improves the oxidized/reduced albumin ratio in patients with liver cirrhosis. Hepatol Res. 2007;37:765–70.PubMedCrossRef
12.
Terawaki H, Yoshimura K, Hasegawa T, Matsuyama Y, Negawa T, Yamada K, et al. Oxidative stress is enhanced in correlation with renal dysfunction: examination with the redox state of albumin. Kidney Int. 2004;66:1988–93.PubMedCrossRef
13.
Terawaki H, Matsuyama Y, Era S, Matsuo N, Ikeda M, Ogura M, et al. Elevated oxidative stress measured as albumin redox state in continuous ambulatory peritoneal dialysis patients correlates with small uraemic solutes. Nephrol Dial Transpl. 2007;22:968.CrossRef
14.
Matsuyama Y, Terawaki H, Terada T, Era S. Albumin thiol oxidation and serum protein carbonyl formation are progressively enhanced with advancing stages of chronic kidney disease. Clin Exp Nephrol. 2009;13:308–15.PubMedCrossRef
15.
Suzuki E, Yasuda K, Takeda N, Sakata S, Era S, Kuwata K, et al. Increased oxidized form of serum albumin in patients with diabetes mellitus. Diabetes Res Clin Pract. 1992;18:153–8.PubMedCrossRef
16.
Hayakawa A, Kuwata K, Era S, Sogami M, Shimonaka H, Yamamoto M, et al. Alteration of redox state of human serum albumin in patients under anesthesia and invasive surgery. J Chromatogr B. 1997;698:27–33.CrossRef
17.
Kawai K, Yoh M, Hayashi T, Imai H, Negawa T, Tomida M, et al. Observation for redox state of human serum and aqueous humor albumin from patients with senile cataract. Tokai J Exp Clin Med. 2001;26:93–9.PubMed
18.
Tomida M, Ishimaru J, Murayama K, Kajimoto T, Kurachi M, Era S, et al. Intra-articular oxidative state correlated with the pathogenesis of disorders of the temporomandibular joint. Br J Oral Maxillofac Surg. 2004;42:405–9.PubMedCrossRef
19.
Ashfaq S, Abramson JL, Jones DP, Rhodes SD, Weintraub WS, Hooper WC, et al. The relationship between plasma levels of oxidized and reduced thiols and early athelosclerosis in healthy adults. J Am Coll Cardiol. 2006;47:1005–11.PubMedCrossRef
20.
Ashfaq S, Abramson JL, Jones DP, Rhodes SD, Weintraub WS, Hooper WC, et al. Endothelial function and aminothiol biomarkers of oxidative stress in healthy adults. Hypertension. 2008;52:80–5.PubMedCrossRef
21.
Gonçalves S, Pecoits-Filho R, Perreto S, Barberato SH, Stinghen AE, Lima EG, et al. Associations between renal function, volume status and endotoxaemia in chronic kidney disease patients. Nephrol Dial Transpl. 2006;21:2788–94.CrossRef
22.
Terawaki H, Yokoyama K, Yamada Y, Maruyama Y, Iida R, Hanaoka K, et al. Low-grade endotoxemia is contributing to chronic inflammation in hemodialysis patients: examination with the novel LPS detection method (ESP method). Ther Apher Dial. 2010;14:477–82.PubMedCrossRef
23.
Szeto CC, Kwan BCH, Chow KM, Lai KB, Chung KY, Leung CB, et al. Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients. Clin J Am Soc Nephrol. 2008;3:431–6.PubMedCrossRef
24.
Sommerburg O, Grune T, Hampl H, Riedel E, van Kuijk FJ, Ehrich JH, et al. Does long-term treatment of renal anemia with recombinant erythropoietin influence oxidative stress in haemodialysed patients? Nephrol Dial Transpl. 1998;13:2583–7.CrossRef
25.
Sela S, Shurtz-Swirski R, Cohen-Mazor M, Mazor R, Chezar J, Shapiro G, et al. Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J Am Soc Nephrol. 2005;16:2431–8.PubMedCrossRef
26.
Anraku M, Kragh-Hansen U, Kawai K, Mariyama T, Yamasaki Y, Takakura Y, et al. Validation of the chloramine-T induced oxidation of human serum albumin as a model for oxidative damage in vivo. Pharm Res. 2003;20:684–92.PubMedCrossRef
27.
Matsuyama Y, Hayashi T, Terawaki H, Negawa T, Terada T, Okano Y, et al. Human astrocytes and aortic endothelial cells actively convert the oxidized form of albumin to the reduced form: reduced albumin might participate in redox regulation of nerve and blood vessel systems. J Physiol Sci. 2009;59:207–15.PubMedCrossRef
28.
Terawaki H, Era S, Nakayama M, Hosoya T. Decrease in reduced-form albumin among chronic kidney disease patients: new insights in cardiovascular complications. Ther Apher Dial. 2011;15:156–60.PubMedCrossRef
29.
Nakayama K, Nakayama M, Iwabuchi M, Terawaki H, Sato T, Kohno M, et al. Plasma α-oxoaldehyde levels in diabetic and nondiabetic chronic kidney disease. Am J Nephrol. 2008;28:1871–8.CrossRef
30.
Tanaka M, Tokunaga K, Komaba H, Itoh K, Matsushita K, Watanabe H, et al. Vitamin D receptor activator reduces oxidative stress in hemodialysis patients with secondary hyperparathyroidism. Ther Apher Dial. 2011;15:161–8.PubMedCrossRef
Metadata
Title
A lower level of reduced albumin induces serious cardiovascular incidence among peritoneal dialysis patients
Authors
Hiroyuki Terawaki
Yukie Matsuyama
Nanae Matsuo
Makoto Ogura
Jun Mitome
Akihiko Hamaguchi
Tomoyoshi Terada
Seiichi Era
Tatsuo Hosoya
Publication date
01-08-2012
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 4/2012
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-012-0610-x

Other articles of this Issue 4/2012

Clinical and Experimental Nephrology 4/2012 Go to the issue

Original Article

Association between the rate of low-birth weight newborns and the incidence of end-stage renal disease in 47 prefectures in Japan

Images in Nephrology

Neurogenic bladder due to a tethered spinal cord

Letter to the Editor

Combined administration of low-dose predonisolone and cyclosporine in idiopathic membranous nephropathy: Tsukuba’s regimen for IMN

Original Article

ANCA-associated systemic vasculitis in Japan: clinical features and prognostic changes

Case Report

Renal cell carcinoma arising from a horseshoe kidney in a chronic hemodialysis patient

Letter to the Editor

Marked elevation of interferon-γ in acute focal bacterial nephritis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits